Ziltivekimab Misses Phase 3 Cardiovascular Endpoint
Novo Nordisk reported that the Phase 3 ZEUS cardiovascular outcomes trial did not reduce major adverse cardiovascular events in more than 6,300 adults with established atherosclerotic cardiovascular disease, chronic kidney disease, and persistent systemic…
